Érick Gamelin

8.2k total citations
138 papers, 6.3k citations indexed

About

Érick Gamelin is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Érick Gamelin has authored 138 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 107 papers in Oncology, 38 papers in Molecular Biology and 31 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Érick Gamelin's work include Colorectal Cancer Treatments and Studies (62 papers), Cancer Treatment and Pharmacology (43 papers) and Gastric Cancer Management and Outcomes (14 papers). Érick Gamelin is often cited by papers focused on Colorectal Cancer Treatments and Studies (62 papers), Cancer Treatment and Pharmacology (43 papers) and Gastric Cancer Management and Outcomes (14 papers). Érick Gamelin collaborates with scholars based in France, United States and Australia. Érick Gamelin's co-authors include M. Boisdron‐Celle, Alain Morel, Laurence Gamelin, R. Delva, S. Brienza, Olivier Coqueret, Norbert Ifrah, Arnaud Vigneron, Stefan Quasthoff and Laura Bossi and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Érick Gamelin

137 papers receiving 6.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Érick Gamelin France 42 4.2k 1.7k 1.0k 714 676 138 6.3k
Jean L. Grem United States 41 3.0k 0.7× 1.8k 1.0× 970 0.9× 268 0.4× 580 0.9× 168 5.9k
M. E. Scheulen Germany 36 2.6k 0.6× 2.3k 1.3× 1.2k 1.1× 370 0.5× 612 0.9× 178 5.5k
R. Bugat France 42 4.4k 1.1× 1.7k 1.0× 1.6k 1.6× 271 0.4× 886 1.3× 181 6.5k
Scott Wadler United States 43 4.5k 1.1× 2.0k 1.2× 1.9k 1.9× 519 0.7× 975 1.4× 192 8.1k
Francesco Cognetti Italy 46 5.0k 1.2× 2.4k 1.4× 2.3k 2.2× 454 0.6× 558 0.8× 221 8.5k
J Carmichael United Kingdom 39 4.8k 1.2× 2.3k 1.3× 1.5k 1.4× 355 0.5× 568 0.8× 76 7.3k
Chris H. Takimoto United States 45 4.8k 1.1× 3.6k 2.1× 2.5k 2.4× 1.0k 1.4× 1.0k 1.5× 193 8.9k
Youcef M. Rustum United States 51 3.7k 0.9× 3.5k 2.1× 1.3k 1.3× 326 0.5× 726 1.1× 246 8.2k
Robert Justice United States 40 2.5k 0.6× 2.8k 1.7× 1.7k 1.6× 442 0.6× 558 0.8× 61 6.4k
K. Mross Germany 37 3.1k 0.7× 2.1k 1.2× 1.0k 1.0× 169 0.2× 361 0.5× 148 5.2k

Countries citing papers authored by Érick Gamelin

Since Specialization
Citations

This map shows the geographic impact of Érick Gamelin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Érick Gamelin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Érick Gamelin more than expected).

Fields of papers citing papers by Érick Gamelin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Érick Gamelin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Érick Gamelin. The network helps show where Érick Gamelin may publish in the future.

Co-authorship network of co-authors of Érick Gamelin

This figure shows the co-authorship network connecting the top 25 collaborators of Érick Gamelin. A scholar is included among the top collaborators of Érick Gamelin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Érick Gamelin. Érick Gamelin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Brugarolas, James, Kathryn E. Beckermann, Brian I. Rini, et al.. (2024). A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma. Clinical Cancer Research. 30(11). 2402–2411. 12 indexed citations
2.
Garon, Edward B., Alexander I. Spira, Melissa L. Johnson, et al.. (2021). A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non–small Cell Lung Cancer. Clinical Cancer Research. 27(16). 4566–4573. 15 indexed citations
3.
Amin, Asim, Mohammed Milhem, Georgina V. Long, et al.. (2019). Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced/metastatic melanoma resistant to anti-PD-1/PD-L1 therapy.. Journal of Clinical Oncology. 37(15_suppl). 9555–9555. 6 indexed citations
4.
Carducci, Michael A., Montaser Shaheen, Ben Markman, et al.. (2018). A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors. Investigational New Drugs. 36(6). 1060–1071. 33 indexed citations
5.
6.
Basseville, Agnès, Laurence Preisser, Sophie de Carné Trécesson, et al.. (2011). Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells. Molecular Cancer. 10(1). 80–80. 47 indexed citations
7.
Vigneron, Arnaud, Érick Gamelin, & Olivier Coqueret. (2008). The EGFR-STAT3 Oncogenic Pathway Up-regulates the Eme1 Endonuclease to Reduce DNA Damage after Topoisomerase I Inhibition. Cancer Research. 68(3). 815–825. 51 indexed citations
8.
Capitain, Olivier, et al.. (2007). The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer. The Pharmacogenomics Journal. 8(4). 256–267. 78 indexed citations
9.
Gamelin, Érick, M. Boisdron‐Celle, Alain Morel, & Olivier Capitain. (2007). Pharmacogénétique des anticancéreux. Annales Pharmaceutiques Françaises. 65(6). 390–401. 1 indexed citations
10.
Boisdron‐Celle, M., et al.. (2006). Neurotoxicité de l’oxaliplatine. Bulletin du Cancer. 93(2). 17–22. 1 indexed citations
11.
Vigneron, Arnaud, et al.. (2006). The Cell Cycle Inhibitor p21 Binds to the myc and cdc25A Promoters upon DNA Damage and Induces Transcriptional Repression. Journal of Biological Chemistry. 281(46). 34742–34750. 56 indexed citations
12.
Barré, Benjamin, Arnaud Vigneron, Neil D. Perkins, et al.. (2006). The STAT3 oncogene as a predictive marker of drug resistance. Trends in Molecular Medicine. 13(1). 4–11. 107 indexed citations
13.
Boisdron‐Celle, M., S Traoré, A Poirier, et al.. (2006). 5-Fluorouracil-related severe toxicity: A comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Letters. 249(2). 271–282. 173 indexed citations
14.
15.
Boisdron‐Celle, M., et al.. (2002). Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences. Cancer Chemotherapy and Pharmacology. 49(3). 235–243. 18 indexed citations
16.
Gamelin, Érick, Laurence Gamelin, Laura Bossi, & Stefan Quasthoff. (2002). Clinical aspects and molecular basis of oxaliplatin neurotoxicity: Current management and development of preventive measures. Seminars in Oncology. 29(5 Suppl 15). 21–33. 251 indexed citations
17.
Boisdron‐Celle, M., et al.. (2001). Pharmacocinétique clinique comparative des dérivés du platine. Bulletin du Cancer. 88(7). 1 indexed citations
18.
Lortholary, Alain, et al.. (2001). Carcinoma of unknown primary site: 311 cases. Bulletin du Cancer. 88(6). 3 indexed citations
19.
20.
Gamelin, Érick, M. Boisdron‐Celle, Alain Turcant, et al.. (1997). Rapid and sensitive high-performance liquid chromatographic analysis of halogenopyrimidines in plasma. Journal of Chromatography B Biomedical Sciences and Applications. 695(2). 409–416. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jean L. Grem Breakdown of academic impact, for papers by M. E. Scheulen Breakdown of academic impact, for papers by R. Bugat Breakdown of academic impact, for papers by Scott Wadler Breakdown of academic impact, for papers by Francesco Cognetti Breakdown of academic impact, for papers by J Carmichael Breakdown of academic impact, for papers by Chris H. Takimoto Breakdown of academic impact, for papers by Youcef M. Rustum Breakdown of academic impact, for papers by Robert Justice Breakdown of academic impact, for papers by K. Mross
Rankless by CCL
2026